FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3017384805> ?p ?o ?g. }

• W3017384805 abstract "Background and importance Biosimilar drugs should have proven clinical efficacy comparable with the referring brand to obtain authorisation from medicine regulatory agencies. Nevertheless, the effectiveness and safety of off-label uses are not always proved. Aim and objectives The endpoint of this study was to evaluate the early effectiveness and safety of biosimilar rituximab compared with the referring brand for an off-label use: glomerular inflammatory renal disease. Material and methods This was an observational retrospective study in patients with glomerular inflammatory disease treated with rituximab (1 g single dose or 1 g two doses). Patients receiving rituximab for the first time between March 2018 and March 2019 were included. Information on patient demographics, underlying disease and associated treatment was collected from the patient medical records. Laboratory data including creatinine, proteinuria, leucocyte and lymphocyte count were collected before (0–60 previous days) and after (0–60 days after) administration of rituximab. Results Six patients (mean age 59 years (26–74); 50% women) with baseline 6.52±2.00×109/L leucocyte count, 2.28±1.10×109/L lymphocyte count, 1.63±1.04 mg/dL creatinine and 6.84±3.36 g/24 hours proteinuria were treated with biosimilar rituximab. Thirteen patients (mean age 58 years (25–81); 30% women) with baseline 9.80±4.62×109/L leucocyte count, 1.92±1.13×109/L lymphocyte count, 1.61±0.85 mg/dL creatinine and 5.81±4.55 g/24 hours proteinuria were treated with brand rituximab. After rituximab administration, these values were 6.13±1.94×109/L leucocyte count, 1.30±0.59×109/L lymphocyte count, 1.16±1.19 mg/dL creatinine, 3.29±0.58 g/24 hours and proteinuria for the biosimilar group, and 8.77±3.78×109/L leucocyte count, 1.67±1.13×109/L lymphocyte count, 1.56±1.19 mg/dL creatinine and 3.36±2.20 g/24 hours proteinuria for the brand group. After rituximab administration, CD19+ lymphocytes become negative in both groups (5/5 for the biosimilar group; 6/6 for the brand group). There were two total remissions, one partial remission and three non-responses with the biosimilar rituximab, and one total remission, five partial remissions and seven non-responses with the brand rituximab. Biosimilar rituximab was well tolerated in 6/6 patients and no infections developed. Brand rituximab was well tolerated in 11/13 patients and 4/13 patients showed an infectious episode. No significant differences were observed for the treatment response between the two groups. Conclusion and relevance Biosimilar rituximab showed an effectiveness and safety profile similar to brand rituximab. Nevertheless, the small sample limits the statistical power and suggests a larger study is required to confirm these results, which we are currently working on. References and/or acknowledgements No conflict of interest." @default.
• W3017384805 created "2020-04-24" @default.
• W3017384805 creator A5001990428 @default.
• W3017384805 creator A5008359527 @default.
• W3017384805 creator A5047915800 @default.
• W3017384805 creator A5053948093 @default.
• W3017384805 creator A5062356953 @default.
• W3017384805 creator A5073029227 @default.
• W3017384805 creator A5079309137 @default.
• W3017384805 creator A5082193090 @default.
• W3017384805 creator A5085831806 @default.
• W3017384805 date "2020-03-01" @default.
• W3017384805 modified "2023-10-18" @default.
• W3017384805 title "5PSQ-052 Early results from the effectiveness and safety evaluation of biosimilar rituximab and brand rituximab in glomerular inflammatory disease" @default.
• W3017384805 doi "https://doi.org/10.1136/ejhpharm-2020-eahpconf.369" @default.
• W3017384805 hasPublicationYear "2020" @default.
• W3017384805 type Work @default.
• W3017384805 sameAs 3017384805 @default.
• W3017384805 citedByCount "0" @default.
• W3017384805 crossrefType "proceedings-article" @default.
• W3017384805 hasAuthorship W3017384805A5001990428 @default.
• W3017384805 hasAuthorship W3017384805A5008359527 @default.
• W3017384805 hasAuthorship W3017384805A5047915800 @default.
• W3017384805 hasAuthorship W3017384805A5053948093 @default.
• W3017384805 hasAuthorship W3017384805A5062356953 @default.
• W3017384805 hasAuthorship W3017384805A5073029227 @default.
• W3017384805 hasAuthorship W3017384805A5079309137 @default.
• W3017384805 hasAuthorship W3017384805A5082193090 @default.
• W3017384805 hasAuthorship W3017384805A5085831806 @default.
• W3017384805 hasBestOaLocation W30173848051 @default.
• W3017384805 hasConcept C126322002 @default.
• W3017384805 hasConcept C2779338263 @default.
• W3017384805 hasConcept C2779561371 @default.
• W3017384805 hasConcept C2780091579 @default.
• W3017384805 hasConcept C2780306776 @default.
• W3017384805 hasConcept C2780653079 @default.
• W3017384805 hasConcept C59491497 @default.
• W3017384805 hasConcept C71924100 @default.
• W3017384805 hasConceptScore W3017384805C126322002 @default.
• W3017384805 hasConceptScore W3017384805C2779338263 @default.
• W3017384805 hasConceptScore W3017384805C2779561371 @default.
• W3017384805 hasConceptScore W3017384805C2780091579 @default.
• W3017384805 hasConceptScore W3017384805C2780306776 @default.
• W3017384805 hasConceptScore W3017384805C2780653079 @default.
• W3017384805 hasConceptScore W3017384805C59491497 @default.
• W3017384805 hasConceptScore W3017384805C71924100 @default.
• W3017384805 hasLocation W30173848051 @default.
• W3017384805 hasOpenAccess W3017384805 @default.
• W3017384805 hasPrimaryLocation W30173848051 @default.
• W3017384805 hasRelatedWork W11221851 @default.
• W3017384805 hasRelatedWork W16121959 @default.
• W3017384805 hasRelatedWork W2955488 @default.
• W3017384805 hasRelatedWork W4429815 @default.
• W3017384805 hasRelatedWork W475345 @default.
• W3017384805 hasRelatedWork W4842688 @default.
• W3017384805 hasRelatedWork W6491323 @default.
• W3017384805 hasRelatedWork W7558900 @default.
• W3017384805 hasRelatedWork W17094598 @default.
• W3017384805 hasRelatedWork W5744107 @default.
• W3017384805 isParatext "false" @default.
• W3017384805 isRetracted "false" @default.
• W3017384805 magId "3017384805" @default.
• W3017384805 workType "article" @default.